An observational study of outcomes in adult lupus nephritis patients : a nationwide retrospective cohort study.

An observational study of outcomes in adult lupus nephritis patients : a nationwide retrospective cohort study. - Study of outcomes of lupus nephritis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000024090

Enrollment

600

Registered

2016-09-16

Start date

2016-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lupus nephritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Already registered in J-RBR before Sep 17, 2013 2)Received renal biopsy between Jan 1, 2007 and Dec 31, 2012 3)18 years old or older at the time of biopsy 4)Fulfilled 4 or more of the ACR criteria for the classification of SLE 5)Registered with a histological diagnosis of lupus nephritis 6)Japanese

Exclusion criteria

Exclusion criteria: 1)No medical records at 6 months or later after renal biopsy. Patients who reached a 50% increase in serum creatinine, end stage renal failure requiring renal replacement therapy or died were not excluded. 2)Insufficient biopsy sample for the diagnosis of ISN/RPS classification 3)Patients who are judged to be inappropriate for the study by the investigator. 4)Patients who decline participation of the study.

Design outcomes

Primary

Measure	Time frame
Doubling of serum creatinine or end-stage renal disease requiring renal replacement therapy	—

Secondary

Measure	Time frame
1) A 50% increase in serum creatinine 2) End-stage renal disease requiring renal replacement therapy 3) Good renal outcome (serum creatinine =< 1.0mg/dl, at the final observation) 4) Death 5) Cardiovascular diseases 6) Malignant tumor 7) Complete remission at 6 months after initiation of treatment (or renal biopsy) 8) Complete remission at 12 months after initiation of treatment (or renal biopsy) 9) Repeat biopsy	—

Measure

Time frame

1) A 50% increase in serum creatinine 2) End-stage renal disease requiring renal replacement therapy 3) Good renal outcome (serum creatinine =< 1.0mg/dl, at the final observation) 4) Death 5) Cardiovascular diseases 6) Malignant tumor 7) Complete remission at 6 months after initiation of treatment (or renal biopsy) 8) Complete remission at 12 months after initiation of treatment (or renal biopsy) 9) Repeat biopsy

—

Countries

Japan

Contacts

Public ContactHidekazu Ikeuchi

Gunma University Hospital Division of Nephrology and Rheumatology

hikeuchi@gunma-u.ac.jp027-220-8166

Outcome results